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Bacteria establish stable communities, known as
biofilms, that are resistant to antimicrobials. Biofilm
robustness is due to the presence of an extracellular
matrix, which for several species—among them
Bacillus subtilis—includes amyloid-like protein
fibers. In this work, we show that B. subtilis biofilms
can be a simple and reliable tool for screening of
molecules with antiamyloid activity. We identified
two molecules, AA-861 and parthenolide, which
efficiently inhibited biofilms by preventing the forma-
tion of amyloid-like fibers. Parthenolide also disrup-
ted pre-established biofilms. These molecules also
impeded the formation of biofilms of other bacterial
species that secrete amyloid proteins, such as
Bacillus cereus and Escherichia coli. Furthermore,
the identified molecules decreased the conversion
of the yeast protein New1 to the prion state in a
heterologous host, indicating the broad range of
activity of the molecules.
INTRODUCTION
Bacteria have the propensity to aggregate on any surface in
ordered communities termed biofilms (O’Toole et al., 2000).
To form biofilms, bacteria secrete a matrix made up of a variety
of molecules, sometimes including amyloid-like fibers (Blanco
et al., 2012). Amyloid proteins were initially diagnosed as the
etiological agent of important human diseases such as
Alzheimer or Parkinson (Murphy, 2002). Based on their patho-
genicity, amyloid proteins were originally thought to be ex-
clusively nonfunctional misfolded proteins. The amyloid fold
results in proteolysis-resistant fibers with characteristic
morphological and biochemical properties. However, the ability
to fold into an amyloid state is a property shared by many
proteins and peptides, and it is not necessarily related to path-
ogenesis (Blanco et al., 2012; Dobson, 2004; Fowler et al.,
2007; Maury, 2009). Indeed, functional proteins that fold into
an amyloid state have been found in different microorganisms
(Blanco et al., 2012; Chapman et al., 2002; Claessen et al.,
2002; Dueholm et al., 2010; Gebbink et al., 2005; Romero
et al., 2010; Wo¨sten and de Vocht, 2000). A role for these
proteins in cell-cell interactions, cell-surface interactions, and
biofilm formation has been demonstrated, and they have thus102 Chemistry & Biology 20, 102–110, January 24, 2013 ª2013 Elsevbeen designated functional amyloid proteins (Badtke et al.,
2009; Maury, 2009). Efforts to understand the nature of amyloid
folding have led to screens for molecules that might inhibit the
aggregation of these proteins. To date, a variety of molecules
have been found to affect the polymerization of amyloid
proteins responsible for important human disorders or be
involved in biofilm formation and virulence of the uropathogenic
bacterium Escherichia coli (Amijee et al., 2009; Cegelski et al.,
2009; Nie et al., 2011).
Bacillus subtilis forms robust floating biofilms (pellicles) in
standing liquid cultures. The most striking visual feature of
such pellicles is their extensive degree of wrinkling. The forma-
tion of biofilms is dependent on the secretion of the protein
TasA and its assembly into amyloid-like fibers (Branda et al.,
2006; Romero et al., 2010). The disassembly of biofilms relies
on the detachment of these fibers from cell surfaces (Kolod-
kin-Gal et al., 2010; Romero and Kolter, 2011). In this study,
we showed that B. subtilis biofilms can be used as a simple
and reliable biological system to screen for molecules with anti-
biofilm and/or antiamyloid activity. Using this system, we found
two molecules, AA-861 and parthenolide, that arrested biofilm
formation by B. subtilis, E. coli, and Bacillus cereus. We also
showed that both molecules interfere with the polymerization
of TasA into amyloid-like fibers. Further, these two molecules
inhibited conversion of the yeast New1 protein to the prion
state.
RESULTS
Screening for Antibiofilm Molecules
At the air-liquid interface of standing liquid cultures, B. subtilis
forms biofilms with wrinkles as a key distinguishable feature.
Alterations of this phenotype have been used to screen collec-
tions of mutants and define regulatory genes and genes re-
sponsible for the synthesis of structural components of the
extracellular matrix (Branda et al., 2004). We used the simplicity
of this experimental setup as a principle to screen for molecules
with antibiofilm activity. We obtained a small collection of
known bioactive molecules from the BIOMOL–ICCB Known
Bioactives collection from the ICCB Longwood Screening
Facility (Harvard Medical School, Boston, MA, USA). The collec-
tion originated from BIOMOL International, LP (Plymouth
Meeting, PA, USA). The complete list of molecules in the known
bioactives collection can be found at the following URL:
http://iccb.med.harvard.edu/libraries/compound-libraries/. The
collection was screened using a 384-well plate and positive
hits were selected based on the absence of wrinkled pelliclesier Ltd All rights reserved
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AA-861 parthenolide Figure 1. Screening of Molecules with
Antibiofilm Activity
384-well microplates filled with MSgg medium
were inoculated with B. subtilis 3610 cells and
aliquots of a collection of small molecules at a final
concentration of 12.5 mg/ml were added. After
24 hr of incubation, plates were assessed for
presence or absence of pellicles.
(A) A close view of one of the plates showing
the inhibition of pellicle provoked by two different
molecules.
(B and C) Structure of AA-861, a benzoquinone
derivative (B), and parthenolide, a sesquiterpene
lactone (C).
(D) A growth curve of B. subtilis 3610 in MSgg
liquid medium showed no variation in bacterial
growth in the absence (B) or presence of 50 mM
AA-861 (-), or parthenolide ( 3 ).
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mammalian cellular targets and/or biological activities have
been well characterized. Two molecules, AA-861, a benzoqui-
none derivative (Figure 1B), and parthenolide, a sesquiterpene
lactone (Figure 1C), inhibited the formation of B. subtilis biofilms
(Figure 1A). A growth curve of cells grown in the presence or
absence of these molecules showed that the concentration
employed in the biofilm assay did not affect bacterial growth
(Figure 1D).
The Antibiofilm Molecules Act on the TasA Amyloid
Protein
The B. subtilis extracellular matrix is made up of two main
components: an exopolysaccharide (EPS) and the amyloid-like
fibers formed by the TasA protein (Branda et al., 2006; Romero
et al., 2010). We hypothesized that the antibiofilm compounds
could function to target one of the components of the extracel-
lular matrix. Both EPS and TasA contribute to biofilm formation,
and only a mutant lacking both of these components is
completely defective in pellicle formation (Branda et al., 2006).
Thus, we could distinguish which component is affected by
analyzing the effect of the compounds on mutants lacking either
TasA or EPS. To test this, we analyzed the effect of the
compounds on wild-type cells, individual eps or tasA mutants,
and a double mutant lacking both components of the extracel-
lular matrix, in 24-well microtiter dishes. As observed in our
primary screen, both molecules prevented the formation of
wrinkly pellicles when added at a concentration of 50 mM,
whereas the DMSO control looked similar to the untreated
sample (Figure 2). The eps mutant grew as previously seen,
forming a fragile broken pellicle, but this pellicle was completely
inhibited in the presence of AA-861 and partially inhibited withChemistry & Biology 20, 102–110, January 24, 2013parthenolide. In contrast, a tasA mutant
was refractory to the activity of both
molecules and produced the same thin
and easily disrupted pellicles as the
untreated controls (Figure 2). This
suggested that both compounds could
specifically target the protein component
of the matrix. As expected, a tasA eps
double mutant lacking both componentsof the extracellular matrix produced no pellicles under all
conditions.
The Antibiofilm Activity Is Not Related to Inhibition of
tasA Gene Expression
The identifiedmoleculesarenot toxic toB.subtiliscells (Figure1D)
and they appear to target TasA specifically (Figure 2). We there-
fore wanted to evaluate whether the antibiofilm activity was due
to a reduction in the expression level of the tasA gene. To test
this, we used the transcriptional fusion of the promotor of the
tasAoperon to the yfpprotein (PtapA-yfp) andanalyzedexpression
of this reporter using flow cytometry (Vlamakis et al., 2008). As
previously observed, after 24 hr of incubation, most untreated
wild-type cells expressed PtapA-yfp (Figure S1A available online).
The addition of either AA-861 or parthenolide did not alter the
expression pattern significantly. In addition, TasA protein could
be detected at similar levels in the matrix and in the medium
before and after treatment with these two compounds (Fig-
ure S1B). We noted a slight decrease in TasA protein levels in
the cell-associated fraction of treated cells relative to untreated
control. However, because this did not correspond to a decrease
in the protein outside of cells (matrix or medium fraction), we do
not believe this could account for the biofilm inhibition. These
results indicated that the molecules do not appear to alter tasA
transcription or TasA localization. Therefore, we hypothesized
that the molecules might inhibit biofilm formation by physically
interfering with the assembly of the TasA amyloid fibers.
The Antibiofilm Activity Is due to Inhibition of TasA
Polymerization
Next, we tested if AA-861 and parthenolide might inhibit the
polymerization of TasA amyloid-like fibers on the cell surface.ª2013 Elsevier Ltd All rights reserved 103
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tasA eps 
tasA 
DMSO Figure 2. TasA Is the Main Target of the
Antibiofilm Molecules
Biofilm assays were performed to determine the
main target of AA-861 and parthenolide. MSgg
mediumwas inoculated with cells of wild-type, eps
or tasA singlemutants, or double tasA, epsmutant.
The molecules were added at 50 mM. DMSO was
used as a negative control. Images of pellicles
were taken after 24 hr of incubation at 30Cwith no
agitation.
See also Figures S1 and S2.
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labeling to study the localization of TasA in cells of biofilms after
24 hr of growth. In untreated controls, TasA formed long fibers
that emanated from cells and were decorated with gold-labeled
anti-TasA antibodies (Figures 3A and 3E). DMSO-treated cells
looked similar to the untreated cells (Figures 3B and 3F). In
contrast, gold-labeled antibodies remained associated to the
cell surface and no fibers were apparent in cells treated with
50 mM of either AA-861 (Figures 3C and 3G) or parthenolide
(Figures 3D and 3H).
These findings favored the hypothesis that the antibiofilm
activity of these molecules is due to the fact that they prevent
the assembly of TasA into functional amyloid-like fibers. We
have previously demonstrated that the formation of TasA fibers
requires at least two proteins, TasA and TapA (Romero et al.,
2010, 2011). TasA is the major subunit of the fibers and TapA
is a minor constituent that is necessary for the initiation of fiber
polymerization and the anchoring of the fibers to the cell surface
(Romero et al., 2011). Therefore, we asked whether the inhibitory
effect of these molecules could be overcome by increasing the
amount of TasA or TapA protein. To test this, we performed
biofilm assays with two strains, DR6 (Phypespank-tasA) and DR8
(Phyperspank-tapA), expressing either TasA or TapA under the
control of an isopropyl b-D-1-thiogalactopyranoside (IPTG)-
inducible promoter. The strain overproducing TasA formed
robust pellicle in the presence of parthenolide similar to the
untreated or DMSO-treated cells, and an improved pellicle in
the presence of AA-861 relative to the wild-type cells treated
with this molecule. In contrast, the strain overproducing TapA
showed the same sensitivity to the molecules as the wild-type104 Chemistry & Biology 20, 102–110, January 24, 2013 ª2013 Elsevier Ltd All rights reservestrain (Figure S2). Thus, we conclude
that the two molecules inhibited biofilm
formation by interfering with the assembly
of TasA into amyloid-like fibers.
The Molecules Obstruct the
Formation of TasA Amyloid-like
Fibers In Vitro
To further determine if both molecules
inhibit TasA polymerization we studied
the kinetics of TasA polymerization
using an in vitro assay with thioflavin
T. Thioflavin T displays increased fluores-
cence at 495 nm when it is bound to the
b sheet-rich fold found in amyloids. For
this analysis, purified TasA was firsttreated with formic acid. After vacuum drying, the protein was
resuspended in physiological buffer with thioflavin T, with or
without the addition of 50 mM AA-861 or parthenolide. For
TasA resuspended in buffer (B) or with DMSO (:), the fluores-
cence signal increased rapidly and reached a maximum after
100 min (Figure 4A). Both AA-861 and parthenolide reduced
the increase in fluorescence, albeit to different levels. First,
a delay in the initiation of the increase in fluorescence was
observed in the presence of both molecules. After 100 min, the
parthenolide-treated sample (,) displayed a small and slow
increase in fluorescence. In contrast, no substantial increase in
fluorescence was observed in the presence of AA-861 (C).
Neither molecule displayed background fluorescence in these
conditions when assayed without protein. To confirm a loss of
fiber formation, after 24 hr of incubation the samples were
analyzed by electron microscopy. In the untreated or DMSO-
treated controls, fibers could be observed (Figures 4B and 4C).
In contrast, AA-861 prevented fiber formation and only small
aggregates were observed (Figure 4D). Parthenolide allowed
the formation of small fibers and disorganized aggregates (Fig-
ure 4E). It thus appears that these molecules do indeed inhibit
TasA polymerization into fibers.
We then wanted to test whether AA-861 and
parthenolide could destroy preformed biofilms in vivo. To test
this, we analyzed pellicles of wild-type and eps mutant strains.
We used the eps mutant to generate weaker pellicles that were
totally dependent on TasA fibers, because our previous data
indicate that TasA was the primary target of the molecules.
This increased the sensitivity of the assay in order to better visu-
alize the effect of the molecules. Pellicles were grown for 12 hrd
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B Figure 3. The Molecules Inhibit Fibers
Formation in Cell Surfaces
Transmission electron micrographs of negatively
stained, anti-TasA immunogold labeled samples
from pellicles grown for 24 hr in MSgg medium.
(A and B) Untreated cells (A) or cells treated with
DMSO as a negative control (B) show wild-type
fibers.
(C and D) Cells treated with 50 mM AA-861 (C) and
parthenolide (D) did not show fibers although the
gold-labeled antibodies remained associated to
cell surfaces.
(E–H) Magnified view of areas marked in (A–D).
Scale bars represent 100 nm in (A–D) and 200 nm
in (E)–(H).
See also Figure S2.
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prior to visualization 12 hr later (Figure 5). Concentrations of AA-
861 of 100 mM to 200 mM were necessary to observe any signif-
icant inhibition of biofilm, with amore dramatic effect observed in
the epsmutant. Parthenolide was more effective, and a concen-
tration of 100 mM was sufficient to promote the destruction of
12-hr-old pellicles.
The Molecules Work Additively to Inhibit Biofilm
Formation
All of our results indicated that AA-861 and parthenolide might
antagonize TasA in different ways. While AA-861 was more
efficient at inhibiting polymerization of the fibers (Figure 4),
parthenolide was more potent at destroying preformed biofilms
(Figure 5). Therefore, we asked whether these molecules might
work additively to inhibit biofilm formation. In order to test this,
we performed pellicle assays of wild-type strains using concen-
trations of eachmolecule that failed to inhibit biofilm formation. A
concentration of 20 mM either AA861 or parthenolide separately
had no effect on biofilm formation relative to the untreated
samples (Figure 6A). However, a combination of both molecules
at a final concentration of 40 mM (20 mM each) completely
inhibited the formation of pellicles. No inhibitory activity was
observedwhen the concentration of eachmolecule was reduced
to 10 mM (Figure S3). Transmission electron microscopy coupled
with immunogold labeling proved that TasA was associated to
cell surfaces of the wild-type strain treated with the combination
of both molecules as indicated by the presence of gold particles,
but TasAwas no longer observed in the form of fibers (Figures 6B
and 6C). Untreated cells produced dense and highly labeled
fibers attached to the cells (Figures 6D and 6E).
The Molecules Affect Other Amyloid Proteins
We have shown that AA-861 and parthenolide efficiently inhibit
the formation of B. subtilis biofilms by inhibiting polymerization
of the amyloid-like fibers of TasA. In order to determine the anti-
biofilm potency of these molecules and their specificity toward
amyloid proteins, we tested them against a subset of bacterial
pathogens, two Gram-negative species, E. coli and Pseudo-
monas aeruginosa, and two Gram-positive species, B. cereus
and Staphylococcus aureus. Of these bacteria, E. coli is known
to produce the amyloid fiber Curli, and B. cereus, though not
reported to produce amyloid proteins, contains homologs of
the tasA gene. All of these organisms form surface-attachedChemistry & Biology 20, 102biofilms (unlike the floating pellicle of B. subtilis) and these bio-
films can be quantified using a standard crystal violet assay
(O’Toole and Kolter, 1998). The untreated controls were normal-
ized to 100% of biofilm formation, and the treatments with
DMSO, AA-861, or parthenolide were expressed as percentages
of the untreated value (Figure 7A). The activity of thesemolecules
varied depending on the bacterial species. Both were effective at
preventing the formation of biofilms by E. coli and B. cereus.
However, they did not show any detectable antibiofilm activity
against S. aureus and P. aeruginosa, organisms not thought to
produce an amyloid component during biofilm formation. These
findings support the specific antiamyloid activity of AA-861 and
parthenolide.
Because both AA-861 and parthenolide showed activity
against bacterial amyloid proteins, we assessed their effect on
a nonbacterial amyloid protein, the New1 yeast prion (Garrity
et al., 2010). In order to do this, we used the E. coli strain
SG811, expressing the N-terminal amyloidogenic domain of
New1 fused to cyan fluorescent protein (CFP) and under control
of an IPTG-inducible promotor. New1 has the ability to convert to
the prion state upon IPTG induction in this heterologous system
(Garrity et al., 2010). Cultures of SG811 were induced with 5 mM
IPTG and incubated with 120 mM DMSO (negative control), AA-
861, or parthenolide, at 30C for 24 hr. We increased the concen-
tration of molecules from the 50 mM that was used inB. subtilis to
120 mM for this experiment because the lower concentration was
ineffective in this assay. A concentration of 120 mM is similar to
the concentration used in other reports detect activity of amyloid
inhibitors (Cegelski et al., 2009; Roberts et al., 2009). The aggre-
gation of the prion domain was confirmed using fluorescence
microscopy by the presence of a bright focus in the cells (Fig-
ure 7B, upper panel). Interestingly, a reduction in the number
of cells accumulating a focus was observed after treatment
with AA-861 (Figure 7B,middle panel) or parthenolide (Figure 7B,
lower panel). To quantify these results, we estimated the number
of cells with a focus (Figure 7C) and the average intensity of the
focus (Figure 7D). In comparison to untreated or DMSO controls,
a decrease in the percentages of cells with a focus was obtained
with AA-861 (40%) and parthenolide (31%). These differences
were more striking when the average intensity of each focus
was compared (Figure 7D). Indeed, reductions between 55%
and 60% were observed in the treatment with parthenolide or
AA-861, respectively. These results indicate that both molecules
target the aggregation of amyloid proteins of different origins.–110, January 24, 2013 ª2013 Elsevier Ltd All rights reserved 105
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Figure 4. The Molecules Inhibit the Polymerization of TasA In Vitro
(A) Thioflavin T and fluorescence were used to study the kinetics of polymer-
ization of TasA. Purified TasA was treated with formic acid, dried under
vacuum and mixed with physiological buffer (B) or DMSO (:), plus 50 mM of
AA-861 (C) or parthenolide (,).
(B–E) Transmission electron micrographs of samples taken after 24 hr of
incubation of TasA in buffer (B), TasA treated with DMSO (C), TasA treated with
AA-861 (D), and TasA treated with parthenolide (E). Scale bars represent
100 nm.
Chemistry & Biology
Biofilm Inhibitors that Target Amyloid ProteinsDISCUSSION
In this study, we show that B. subtilis biofilms are effective for
screening for molecules with antibiofilm and/or antiamyloid
properties. Among a collection of hundreds of known bioactive
molecules, we found two that efficiently inhibited biofilm forma-
tion by specifically targeting amyloids. One of them, AA-861,
is a benzoquinone derivative with anti-inflammatory activity
(Yoshimoto et al., 1982). The other, parthenolide, is a sesquiter-
pene lactone with anti-inflammation and anticancer activities
(Mathema et al., 2012). It has been shown for certain molecules
that antiamyloid activity results from molecule aggregates and
not monomers (Feng et al., 2008). Whether the inhibitory activity
of these compounds is due to monomers or aggregates is
unclear at this time.106 Chemistry & Biology 20, 102–110, January 24, 2013 ª2013 ElsevThe anti-inflammatory activity of AA-861 is exerted by
competing with the enzyme 5-lipoxigenase, which provokes
a reduction of the levels of leukotrienes, and as a consequence,
a decrease in the aggressiveness of inflammation associated
with diverse human diseases (Titos et al., 2003). Besides this
main biological activity, AA-861 was later shown to slightly
reduce amyloid formation of amylin, the amyloid polypeptide
found in human pancreatic islet (Tomiyama et al., 1997). These
findings support our conclusion that the antibiofilm effect of
AA-861 could result from preventing the TasA protein from
forming functional amyloid-like fibers. Indeed, our in vitro
experiments supported this hypothesis as AA-861 arrested the
aggregation of TasA into fibers. The mechanism by which AA-
861 and other quinone derivatives reduce amyloidogenesis still
remains obscure. However, it is likely that a direct interaction
of AA-861 with different forms of the amyloid proteins could
impede the polymerization of the fiber as is observed with
rifampicin, which has antiamyloid activity against amylin and
a-synuclein, the peptide responsible for Parkinson disease (Li
et al., 2004).
Parthenolide is a natural product found in the plant Tanacetum
parthenium (feverfew), which has been used as an herbal
treatment to reduce fever and pain. There has been some scien-
tific interest in parthenolide because it has been shown to have
anticancer and anti-inflammatory activities (Mathema et al.,
2012). However, there are no published studies of the effects
of parthenolide in humans. Here, we have demonstrated that
parthenolide also has an antibiofilm activity by reducing amyloid
fiber formation and destroying preformed biofilms. A dual activity
of being anti-inflammatory and antiamyloid has been previously
reported for another group of molecules, the nonsteroidal anti-
inflammatory drugs (NSAIDs) (Gasparini et al., 2004; Weggen
et al., 2001). Epidemiological studies found that patients treated
with NSAIDs had a low propensity of suffering from Alzheimer
disease (Szekely and Zandi, 2010). Whether parthenolide could
exhibit similar effects remains to be determined.
We have additionally shown that the antibiofilm activity of
AA-861 and parthenolide is effective against E. coli and
B. cereus. E. coli produces the amyloid fiber Curli, and it was
recently shown that two ring-fused 2-pyridones with pilicide
activity inhibited Curli polymerization. This inhibition of both Curli
and type I pili was correlated with reduced virulence and
a decreased ability of E. coli to colonize host tissues and form
biofilms (Cegelski et al., 2009). B. cereus has not been reported
to form amyloid-like fibers. However, its genome harbors homo-
logs of the B. subtilis TasA protein. Therefore, it is reasonable to
think this homolog might polymerize into amyloid fibers that are
involved in biofilm formation. Though not covered in the study,
we speculate that the molecules could antagonize the formation
of amyloid fibers in E. coli and B. cereus similar to what we have
found in B. subtilis. In contrast, P. aeruginosa and S. aureus are
not reported to have amyloid proteins, and biofilms of these
species were immune to the action of AA-861 and parthenolide,
an observation that pointed toward the specificity of both mole-
cules for amyloid proteins. Finally, thesemolecules were not only
active against bacterial amyloids, but both molecules also
arrested the conversion of the yeast New1 protein to its prion
state. The mechanism by which this inhibition happens remains
to be elucidated. It is important to note that before any moleculeier Ltd All rights reserved
Figure 5. TheMolecules Destroy Preformed
Biofilms
Biofilms of wild-type and epsmutants were grown
in MSgg medium for 12 hr at 30C. Then, DMSO,
AA-861, or parthenolide was added at 100 mM or
200 mM, and pictures of the pellicles were taken
12 hr later.
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must be performed on a variety of amyloids. Indeed, FN075,
a ring-fused 2-pyridone that inhibits Curli fibrillation in E. coli,
actually stimulates amyloid formation of a-synuclein (Horvath
et al., 2012). Our analysis of AA-861 and parthenolide thus far
suggests these molecules may be general inhibitors, because
we have observed inhibition of TasA and New1 aggregation
and inhibition of biofilm formation in E. coli and B. cereus, which
have amyloid proteins as major matrix components.SIGNIFICANCE
In order to form a biofilm, bacterial cells have to produce,
secrete, and assemble different macromolecules into the
network that is the extracellular matrix (Branda et al.,
2005). Amyloid proteins represent key components of the
biofilm matrix of several microorganisms (Maury, 2009;
Romero et al., 2010). These microbial amyloid fibers are
structurally and biochemically similar to the pathogenic
variants found in humans. Therefore, they are good candi-
dates to be used as targets in screens for molecules that
may serve two purposes: antibiofilm and antiamyloid
agents (Cegelski et al., 2009; Nie et al., 2011; Roberts
et al., 2009). In order to screen large libraries of molecules,Untreated AA-861 Parthenolide AA-861+PN 
B E 
A 
D C 
Chemistry & Biology 20, 102–110, January 24, 2013it is important to have simple and
robust assay. In this study, we show
that B. subtilis biofilm inhibition
can provide such an assay. We found
two molecules that efficiently arrestedbiofilm formation. One of them, AA-861, is a benzoquinone
derivative (Yoshimoto et al., 1982), and the other, partheno-
lide, is a sesquiterpene lactone with anticancer and anti-
inflammatory activities (Mathema et al., 2012). We also
showed that these molecules have the ability to arrest
the aggregation of New1, a yeast prion protein. These find-
ings open the door for large-scale screens to identify
additional molecules with similar activities and for
structure-activity relationship studies with the molecules
identified.
EXPERIMENTAL PROCEDURES
Regents and Growth Conditions
AA-861 (A3711), a benzoquinone derivative, and parthenolide (P0667) were
obtained from Sigma and dissolved in DMSO at a concentration of 5 mg/ml.
The molecules were used at final concentration of 50 mM when added from
the beginning to the cultures, 100 mM to 200 mM when added after 12 hr of
growth, and 120 mM in the experiments with New1.
Luria broth (LB) comprised 1% tryptone (Difco), 0.5% yeast extract (Difco),
and 0.5% NaCl. MSgg broth comprised 100 mM morpholinepropane
sulphonic acid (pH 7), 0.5% glycerol, 0.5% glutamate, 5 mM potassium phos-
phate (pH 7), 50 mg/ml tryptophan, 50 mg/ml phenylalanine, 2 mM MgCl2,
700 mM CaCl2, 50 mM FeCl3, 50 mM MnCl2, 2 mM thiamine, and 1 mM ZnCl2
(Branda et al., 2001). Tryptic soy broth (TSB; Sigma Aldrich) was supple-
mented with 0.5% glucose and 3% NaCl. YESCA comprised 1% Casamino
Acids, 0.1% yeast extract. M63 minimal medium comprised 1.2% KH2PO4,Figure 6. The Molecules Inhibit Biofilm
Formation with Additive Effects
(A) The formation of biofilm by the wild-type strain
was evaluated in MSgg medium alone or with the
addition 20 mMof eachmolecule added separately
or in combination (20 mM of each). Pictures of
the wells were taken after 24 hr of incubation at
30C. Transmission electron microscopy and
immunogold labeling were used to determine the
presence or absence of TasA fibers.
(B and C) Cells treated with both molecules
appeared decorated with gold particles but did not
show any TasA fibers.
(D and E) Untreated cells showed long fibers
labeled with gold particles.
(C) and (E) are magnified views of the areas
marked in (B) and (D). Scale bars represent 500 nm
in (B) and (D) and 200 nm in (C) and (E).
See also Figure S3.
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Figure 7. The Molecules Affect Other Amyloid Proteins
(A) Antibiofilm activity against other bacterial species that form surface-adhered biofilms. The crystal violet method was used to quantify biofilm formation. The
absorbance at 590 nm was measured and values were represented relative to untreated controls that were normalized to 100%. The molecules were used at
a final concentration of 50 mM. Untreated cells (black bars), treated with DMSO (hatched bars), AA-861 (unfilled bars), or parthenolide (gray bars).
(B–D) The molecules reduce the aggregation of New1 yeast prion expressed in E. coli cells. Fluorescence and phase contrast microscopy images were taken of
E. coli cells expressing the yeast prion domain New1 fused to CFP and induced with 5 mM IPTG (B, upper panel). A decrease in the number of cells accumulating
New1-CFP foci was observed after treatment with 120 mM AA-861 (B, middle panel) and parthenolide (B, lower panel). The number of cells accumulating New1-
CFP foci was quantified and expressed as percentage of cells with foci (C), and the average intensity of these foci expressed as arbitrary units (D). Ten different
microscopic fields were scored for each condition (counting a total of 1,000 cells) and the percentages were calculated. The data represent the mean ± SD of
three independent experiments.
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-1 MgSO4, 0.2%
glucose, and 0.5% Casamino Acids.
Strains
The strains used in this study were B. subtilis NCIB3610, and derivative
mutants SSB488 (epsA-O::tet), CA017 (tasA::kan), SSB572 (epsA-O::tet
tasA::spc) (Romero et al., 2010), DR6 (tasA::km, lacA:: Phyperspank-tasA, mls)
(Romero et al., 2011), B. cereus ATCC14579, E. coli MC4100, E. coli GS811
(BW27785 attB::ahp lacIq Ptac new150–100-cfp-3xha; produces New1
[residues 50–100] fused to CFP, and three hemagglutinin tags from a chromo-
somal construct integrated at lambda attachment site) (Garrity et al., 2010),
S. aureus, and P. aeruginosa.
To construct the strain DR-8 ([tapA-sipW-tasA]::spc, amyE::[tapA(13-234)-
sipW-tasA] [cm], lacA::Phyperspank-tapA), the mutant strain lacking the tapA-
sipW-tasA operon (SSB149) was transformed by natural competence with
the plasmid pDFR8 and positive clones were used as donor strains for
transferring the constructs into B. subtilis strain mutant (FC268) by means of
SPP1-mediated generalized transduction (Yasbin and Young, 1974). To
generate the plasmid pDFR8 (lacA::Phyperspank-tapA), the open reading frame
of tapA was amplified with the primers TapA-F (50-GGCCATGTCGACTTTTAC
AGGAGGTAAGATATGTTTCGATTG-30) and TapA-R (50-GGCCATGCATGCTT
ACTGATCAGCTTCATTGCTTTTTTC-30). The PCR product was digested with108 Chemistry & Biology 20, 102–110, January 24, 2013 ª2013 ElsevSalI and SphI and cloned into the plasmid pDR111 digested with the same
enzymes. Then, a digest of pDFR-7 with XhoI and BamHI containing the frag-
ment Phyperspank-tapA was cloned into pDR183 digested with the same
enzymes resulting in pDFR8 (lacA::Phyperspank-tapA).
Biofilm Assays
Pellicle formation assay in standing liquid cultures was used to test biofilm
development of B. subtilis. The different strains were grown in MSgg broth in
a 24-well microtiter dish and incubated without agitation at 30C for 48 hr
(Romero et al., 2011). For the screen, library compounds were pin-transferred
to 384-well plates into 30 ml MSgg, followed by addition of 10 ml of an overnight
culture suspension of B. subtilis NCIB3610 in MSgg to a final OD600 of 0.05.
The final concentration of each compound was 12.5 mg/ml. Plates were incu-
bated at 30C for 24 hr, and then scored visually or by measuring OD600. For
screening by OD600, a Z
0 score of 0.71 was determined by comparing the
average and SD of the OD600 obtained on untreated wells or wells harboring
3 mM D-tyrosine, a known inhibitor of biofilm formation in B. subtilis (Kolod-
kin-Gal et al., 2010; Romero and Kolter, 2011). The crystal violet assay was
used to test the formation of biofilm for the rest of the bacterial species, as
previously reported (O’Toole and Kolter, 1998). Briefly, S. aureus was grown
in TSB medium, B. cereus was grown in LB, E. coli was grown in YESCA
and P. aeruginosa in M63 glucose medium. All of them where incubatedier Ltd All rights reserved
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and after 15 min of incubation the amount of biomass attached to the well
surfaces was quantified after solubilizing the dye with 70% ethanol and
measuring the absorbance at 590 nm.
SDS-PAGE and Immunoblot Assays
For localization of TasA within B. subtilis biofilms, pellicles of 24 hr produced in
MSgg broth were fractionated in three biochemical compartments—matrix,
cell, and medium—as previously described (Branda et al., 2006). Protein
preparations were developed in SDS-PAGE with 10% polyacrylamide and
blotted onto polyvinylidene fluoride membrane using standard procedures.
For detection of TasA, blots were probed with anti-TasA antibodies (raised
in rabbits) at dilution 1:20,000. A secondary anti-rabbit immunoglobulin G
antibody conjugated to horseradish peroxidase (Bio-Rad) was used at a
dilution of 1:20,000. Blots were developed using the Pierce super signal detec-
tion system (Pierce, Thermo Scientific).
Flow Cytometry
Biofilms of cells harboring PtapA-yfp fusions (ZK3755 and DR7) were harvested
at 24 hr and dispersed as previously described (Vlamakis et al., 2008). After
fixation in 4% paraformaldehyde solution for 7 min, washes with PBS, and
resuspension in GTE buffer, single cells were obtained by mild sonication
(Branda et al., 2006). For flow cytometric analysis, cell suspensions were
measured on a BD LSR II flow cytometer (BD Biosciences) using a solid-state
laser and a laser excitation of 488 nm coupled with 530/30 and 505LP
sequential filters. The photomultiplier voltage was set at 400–500 V. Every
sample was analyzed by counting 50,000 events using FACS Diva (BD Biosci-
ences) software to capture the data (Lo´pez et al., 2009). Further analysis was
performed using FlowJo 8.7.2 software (http://www.flowjo.com).
In Vitro Assays for Study Assembly of TasA Amyloid-like Fibers
The effect of the different molecules on TasA polymerization was analyzed
using the Thioflavin-T (ThT) assay in 96 microwell plates, as previously re-
ported (Romero et al., 2010). Purified TasA was depolymerized by treatment
with 10% formic acid solution for 2 min. After drying under vacuum in
a Speed-vac at 30C, the remaining product containing TasA was resus-
pended in 50 mM NaCl, 20 mM Tris, (pH 7) buffer or buffer containing the
different molecules at 50 mM and incubated at room temperature. The wells
were previously blocked with 2.5 mg/ml bovine serum albumin in PBS for
2 hr at 30C and shaking. After blocking each well was filled with the following
mixture: 10 mM protein samples, 20 mM ThT solution, PBS buffer, and distilled
water to complete a final volume of 200 ml. The fluorescence was measure in
a spectrophotometer (Spectra Max M2, Molecular Devices, Sunnyvale, CA,
USA) fluorescence plate reader set up at 438 excitation and 495 nm emission,
at 30C and shaking for a total of 24 hr. In this assay, the final concentration of
the molecules was 50 mM.
Transmission Electron Microscopy and Immunolabeling
For negative staining analysis, protein solutions were spotted onto a carbon or
formvar/carbon-coated grid, for a few minutes. The excess of liquid was dis-
charged in a filter paper, and the grids stained with a 1% aqueous uranyl
acetate solution for 2 min.
Immunolocalization of TasA was performed on intact cells from 24 hr bio-
films as previously described (Romero et al., 2011). Briefly, intact cells were
absorbed in hydrophilic carbon-coated grids. Then the samples were blocked
in 1% nonfat dry milk in PBS with 0.1% Tween 20 for 30 min and on anti-TasA
antibodies diluted 1:150 in the same blocking buffer for 2 hr, rinsed in PBST,
and exposed to goat-anti-rabbit 20 nm gold secondary antibody diluted 1:50
(TedPella) for 1 hr, and rinsed. All grids were contrasted with uranyl acetate
as described above for visualization. The samples were examined in a Tecnai
G2 Spirit BioTWIN microscope at an accelerating voltage of 80 KV. Images
were taken with an AMT 2k CCD camera (Romero et al., 2011).
Fluorescence Microscopy
E. coli cells of the strain SG811 (BW27785 attB::ahp lacIq Ptac new150–100-
cfp-3xha; produces New1 [residues 50–100] fused to CFP) were grown in
microtiter plates induced with 5 mM IPTG and incubated with 120 mM AA-
861 or parthenolide. DMSOwas used as a negative control. After 24 hr of incu-Chemistry & Biology 20, 102bation at 30C, cells were pelleted and fixed with a 4% paraformaldehyde
solution for 7 min, washed in PBS, and resuspended in GTE buffer (Romero
et al., 2011). Then 10 ml drops were deposited in slides pretreated with a
thin layer of agarose (1%). Images were taken in a Nikon Eclipse TE2000-U
microscope with X-cite 120 illumination system and a Hamamatsu digital
camera model ORCA-ER. CFP fluorescence signal was taken using the filter
set (Ex436/500). The exposure times were 800 ms. For quantification of cells
accumulating foci and the intensity of the foci, approximately 1,000 cells
were analyzed per treatment. The data represent the mean ± SD of the three
experiments. Image processing was done using MetaMorph Software,
ImageJ, and Photoshop.
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